An immune-boosting treatment for lung cancer patients reduces the risk of cancer relapse after surgery to the same extent as chemotherapy but without the risk of unpleasant side effects, says a Phase II study by Belgian researchers.
The study included 182 patients with non-small-cell lung cancer, the most common form of the disease. All the patients had surgery to remove their cancer and were then randomly assigned to receive either a placebo or MAGE-A3 ASCI (antigen-specific cancer immunotherapeutic) injections over 27 months — five given at three-week intervals, followed by eight given once every three months.
MAGE-A3 is a tumor-specific antigen produced in 35 percent to 50 percent of non-small-cell lung cancer. It’s not produced by normal cells
More, Click Here.
More, Click Here.
...................................................
No comments:
Post a Comment